|
1.
|
Di Renzo MF, Narsimhan RP, Olivero M,
Bretti S, Giordano S, Medico E, Gaglia P, Zara P and Comoglio PM:
Expression of the Met/HGF receptor in normal and neoplastic human
tissues. Oncogene. 6:1997–2003. 1991.
|
|
2.
|
Comoglio PM and Boccaccio C: The HGF
receptor family: Unconventional signal transducers for invasive
cell growth. Genes Cells. 1:347–354. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Jeffers M, Rong S and Vande Woude GF:
Hepatocyte growth factor/scatter factor-Met signaling in
tumorigenicity and invasion/metastasis. J Mol Med. 74:505–513.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Pennacchietti S, Michieli P, Galluzzo M,
Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive
growth by transcriptional activation of the met protooncogene.
Cancer Cell. 3:347–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki
H, Ito H and Tahara E: Frequent amplification of the c-met gene in
scirrhous type stomach cancer. Biochem Biophys Res Commun.
189:227–232. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kijima Y, Hokita S, Yoshinaka H, Itoh T,
Koriyama C, Eizuru Y, Akiba S and Aikou T: Amplification and
overexpression of c-met gene in Epstein-Barr virus-associated
gastric carcinomas. Oncology. 62:60–65. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Nakazawa K, Dobashi Y, Suzuki S, Fujii H,
Takeda Y and Ooi A: Amplification and overexpression of c-erbB-2,
epidermal growth factor receptor, and c-met in biliary tract
cancers. J Pathol. 206:356–365. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Miller CT, Lin L, Casper AM, Lim J, Thomas
DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW and
Beer DG: Genomic amplification of MET with boundaries within
fragile site FRA7G and upregulation of MET pathways in esophageal
adenocarcinoma. Oncogene. 25:409–418. 2006.PubMed/NCBI
|
|
9.
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C,
Johnson BE, Cantley LC and Jänne PA: MET amplification leads to
gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lutterbach B, Zeng Q, Davis LJ, Hatch H,
Hang G, Kohl NE, Gibbs JB and Pan BS: Lung cancer cell lines
harboring MET gene amplification are dependent on Met for growth
and survival. Cancer Res. 67:2081–2088. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Nakamura T, Teramoto H and Ichihara A:
Purification and characterization of a growth factor from rat
platelets for mature parenchymal hepatocytes in primary cultures.
Proc Natl Acad Sci USA. 83:6489–6493. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Birchmeier C and Gherardi E: Developmental
roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends
Cell Biol. 8:404–410. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ullrich A and Schlessinger J: Signal
transduction by receptors with tyrosine kinase activity. Cell.
61:203–212. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Rodrigues GA and Park M:
Autophosphorylation modulates the kinase activity and oncogenic
potential of the Met receptor tyrosine kinase. Oncogene.
9:2019–2027. 1994.PubMed/NCBI
|
|
16.
|
Ma PC, Tretiakova MS, Nallasura V,
Jagadeeswaran R, Husain AN and Salgia R: Downstream signalling and
specific inhibition of c-MET/HGF pathway in small cell lung cancer:
Implications for tumour invasion. Br J Cancer. 97:368–377. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Henne WM, Buchkovich NJ and Emr SD: The
ESCRT pathway. Dev Cell. 21:77–91. 2011. View Article : Google Scholar
|
|
18.
|
Yarden Y: The EGFR family and its ligands
in human cancer signaling mechanisms and therapeutic opportunities.
Eur J Cancer. 37:3–8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Woodburn JR: The epidermal growth factor
receptor and its inhibition in cancer therapy. Pharmacol Ther.
82:241–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Baselga J and Averbuch SD: ZD1839
(‘Iressa’) as an anticancer agent. Drugs. 60(Suppl 1): S33–S42.
2000.
|
|
21.
|
Arteaga CL and Johnson DH: Tyrosine kinase
inhibitors-ZD1839 (Iressa). Curr Opin Oncol. 13:491–498. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Barker AJ, Gibson KH, Grundy W, Godfrey
AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett
L, Henthorn L and Richards L: Studies leading to the identification
of ZD1839 (IRESSA): an orally active, selective epidermal growth
factor receptor tyrosine kinase inhibitor targeted to the treatment
of cancer. Bioorg Med Chem Lett. 11:1911–1914. 2001. View Article : Google Scholar
|
|
23.
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and
Haber DA: Activating mutations in the epidermal growth factor
receptor underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ,
Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and
Meyerson M: EGFR mutations in lung cancer: correlation with
clinical response to gefitinib therapy. Science. 304:1497–1500.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Nishimura Y, Bereczky B and Ono M: The
EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis
of EGFR via the early/late endocytic pathway in non-small cell lung
cancer cell lines. Histochem Cell Biol. 127:541–553. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Nishimura Y, Yoshioka K, Bereczky B and
Itoh K: Evidence for efficient phosphorylation of EGFR and rapid
endocytosis of phosphorylated EGFR via the early/late endocytic
pathway in a gefitinib-sensitive non-small cell lung cancer cell
line. Mol Cancer. 7:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Nishimura Y, Yoshioka K, Takiguchi S,
Bereczky B, Nakabeppu Y and Itoh K: A role for SNX1 in the
regulation of EGF-dependent phosphorylated EGFR endocytosis via the
early/late endocytic pathway in a gefitinib-sensitive human lung
cancer cells. Curr Signal Transduct Ther. 6:383–395. 2011.
View Article : Google Scholar
|
|
28.
|
Nishimura Y, Takiguchi S, Yoshioka K,
Nakabeppu Y and Itoh K: Silencing of SNX1 by siRNA stimulates the
ligand-induced endocytosis of EGFR and increases EGFR
phosphorylation in gefitinib-resistant human lung cancer cell
lines. Int J Oncol. 41:1520–1530. 2012.PubMed/NCBI
|
|
29.
|
Worby CA and Dixon JE: Sorting out the
cellular function of sorting nexins. Nat Rev Mol Cell Biol.
3:919–931. 2002. View
Article : Google Scholar
|
|
30.
|
Kurten RC, Cadena DL and Gill GN: Enhanced
degradation of EGF receptors by a sorting nexin, SNX1. Science.
272:1008–1010. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zhong Q, Lasar CS, Tronchere H, Sato T,
Meerloo T, Yeo M, Songyang Z, Emr SD and Gill GN: Endosomal
localization and function of sorting nexin 1. Proc Natl Acad Sci
USA. 99:6767–6772. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Carlton J, Bujny M, Peter BJ, Oorschot VM,
Rutherford A, Mellor H, Klumperman J, McMahon HT and Cullen PJ:
Sorting nexin-1 mediates tubular endosome-to-TGN transport through
coincidence sensing of high-curvature membranes and
3-phosphoinositides. Curr Biol. 14:1791–1800. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Gullapalli A, Garrett TA, Paing MM,
Griffin CT, Yang Y and Trejo J: A role for sorting nexin 2 in
epidermal growth factor receptor down-regulation: evidence for
distinct functions of sorting nexin 1 and 2 in protein trafficking.
Mol Biol Cell. 15:2143–2155. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Nishimura Y, Higaki M and Kato K:
Identification of a precursor form of cathepsin D in microsomal
lumen: characterization of enzymatic activation and proteolytic
processing in vitro. Biochem Biophys Res Commun. 148:335–343. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Nishimura Y, Kawabata T and Kato K:
Identification of latent procathepsins B and L in microsomal lumen:
characterization of enzymatic activation and proteolytic processing
in vitro. Arch Biochem Biophys. 261:64–71. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Kornfeld S and Mellman I: The biogenesis
of lysosomes. Ann Rev Cell Biol. 5:483–525. 1989. View Article : Google Scholar
|
|
37.
|
Sandoval IV, Arredondo JJ, Alcalde J,
Gonzalez-Noriega A, Vandekerckhove J, Jimenez MA and Rico M: The
residues Leu (Ile) 475-Ile (Leu) 476, contained in the extended
carboxyl cytoplasmic tail, are critical for targeting of the
resident lysosomal membrane protein LIMPII to lysosomes. J Biol
Chem. 269:6622–6631. 1994.PubMed/NCBI
|
|
38.
|
Bean J, Brennan C, Shih JY, Riely G, Viale
A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang
WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC,
Miller V, Ladanyi M, Yang CH and Pao W: MET amplification occurs
with or without T790M mutations in EGFR mutant lung tumors with
acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci
USA. 104:20932–20937. 2007. View Article : Google Scholar : PubMed/NCBI
|
